What specification parameters define this API grade?

The active pharmaceutical ingredient supplied under the designation Butaphosphan 99% Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable corresponds to 1-(butylamino)-1-methylethylphosphonic acid, CAS registry number 17316-67-5, with the molecular formula C₇H₁₈NO₃P and a molar mass of 195.19 g/mol. The molecular architecture comprises a quaternary carbon centre bearing two methyl substituents, an n-butylamino group, and a free phosphonic acid functionality; this structure delivers a water-soluble, non-halogenated phosphorus donor employed primarily in veterinary metabolic therapy as a stimulator of hepatic gluconeogenesis and a source of metabolically available phosphorus. The compound is manufactured under current Good Manufacturing Practice conditions conforming to ICH Q7, with a minimum assay of 99.0% w/w (anhydrous basis) verified by high-performance liquid chromatography using area normalisation per Ph. Eur. 2.2.29 / USP <621>. Because neither the European Pharmacopoeia nor the United States Pharmacopeia currently publishes a dedicated monograph for butaphosphan, the release specification is constructed from the applicable general chapters and from validated in-house analytical procedures cross-referenced to those compendial methods. Published data for this specific configuration is limited, and batch release therefore depends on the matrix of acceptance criteria tabulated below.

Powder flow behaviour is assessed per USP <1174>; the angle of repose for terminal acetone-water crystallisation batches typically falls within 45–55°, indicating passable-to-cohesive flow that mandates wet granulation for high-speed rotary tablet compression. Lot-specific compressibility indices (Carr index and Hausner ratio) are generated during incoming-material qualification because published literature values for butaphosphan bulk density and tapped density remain limited.

The terminal crystallisation step is executed from an acetone-water binary solvent system that yields elongated platelet morphology with measurable anisotropy in axial versus radial compressibility. This crystallographic characteristic is not cosmetic: it directly governs the lower punch compression force required to achieve a target tablet hardness of 60–90 N and influences the incidence of capping in high-turret-speed operations. For capsule manufacture, the same 99% article is milled or air-jet micronised to a controlled D90 of 150 µm or below to prevent segregation during auger feeding on dosing-disc and dosator-type encapsulation machines. Content uniformity testing per USP <905> is routinely applied for all fill weights below 100 mg API per unit, where the proportion of free-flowing diluents such as anhydrous lactose or microcrystalline cellulose PH-102 increases stratification risk. The production-scale route recommended for tablet manufacture employs a high-shear granulator operated at an impeller speed of 200–300 rpm with an aqueous PVP K30 binder solution at a liquid-to-solid ratio of 8–12% w/w; the wet mass is dried in a fluid-bed dryer at 60–70°C inlet air to a moisture endpoint of 1.0–2.0% w/w before lubrication with 0.5–1.0% w/w magnesium stearate. On rotary presses running at turret speeds of 30–60 rpm, the granulated material supports a compression force window of approximately 8–18 kN without exceeding ejection-force thresholds that induce tooling wear; however, published data for this specific configuration is limited and press parameters must be bracketed during process qualification.

For oral granules administered via feed or drinking water, the same high-shear or fluid-bed granulator platform is employed, with starch-based binders substituted for PVP where regulatory preferences in certain jurisdictions require non-synthetic excipients. Drying endpoint control is critical: residual moisture exceeding 2.5% w/w activates hydrolytic cleavage of the N–butyl bond during extended ambient storage, a degradation pathway detectable as an increase in the butylamine-related impurity signal on HPLC-DAD. The granulated product is typically sized through a 1.0–1.6 mm sieve to achieve the particle size distribution specified for uniform incorporation into meal feed at inclusion rates below 1.0% w/w.

Injectable dosage forms and the burden of endotoxin control

Parenteral application imposes the most restrictive specification burden on the 99% API. The material processed for injectable presentations is chemically identical to the solid-dose grade, but the release protocol adds the bacterial endotoxin acceptance criterion of < 0.25 EU/mg using the Limulus amebocyte lysate kinetic chromogenic method (Ph. Eur. 2.6.14 / USP <85>). The aqueous solubility of the free phosphonic acid permits formulation as a 10% w/v aqueous solution without organic co-solvents; final pH adjustment to 5.5–6.5 with dilute sodium hydroxide generates the monosodium salt in situ while maintaining osmolality within the 285–310 mOsm/kg range specified for isotonic intravenous administration. Sterile filtration through a 0.22 µm PVDF membrane in a double-filter train precedes aseptic filling into Type I borosilicate glass vials; where terminal sterilisation is selected, a standard cycle at 121°C for 15 min (F₀ ≥ 8 min) is applied, and forced-degradation studies per ICH Q1A(R2) confirm the absence of detectable assay loss under these conditions. The absence of a chlorine substituent eliminates the generation of chlorinated hydrolysis products during autoclaving. Published formulations co-administer butaphosphan with cyanocobalamin at concentrations of 100 g/L and 0.05 g/L respectively (corresponding to 100 mg/mL butaphosphan and 50 µg/mL cyanocobalamin) for the supportive treatment of acetonemia and periparturient negative energy balance in dairy cattle. The sterilised aqueous solution remains free of visible precipitation and sub-visible particle counts above pharmacopoeial thresholds for not fewer than 24 months at 25°C / 60% RH in amber glass, supporting suitability for injectable use without in-line particle counting.

When to select 99% butaphosphan over technical or salt forms

The decision to specify a 99% pharma-grade butaphosphan rather than a technical or intermediate purity material is governed by the regulatory chemistry, manufacturing, and controls data requirements of the target dossier. Technical-grade material, with assay values of 95–98% w/w and single-impurity burdens exceeding 1.0% w/w, is unsuitable for parenteral dosage forms because unidentified impurities may include phosphorus-containing condensation products that contribute to turbidity after autoclaving; for oral solid dosage forms, the same technical grade can be used in certain jurisdictions only if the manufacturer provides a complete impurity qualification package meeting ICH Q3A threshold criteria. Salt forms of butaphosphan, including the sodium salt prepared by treating the free acid with one equivalent of sodium hydroxide, differ in hygroscopicity and particle morphology: the sodium salt absorbs moisture more rapidly at relative humidity above 60% and typically requires more aggressive drying after wet granulation, whereas the free acid form maintains acceptable handling characteristics under standard pharmaceutical processing conditions. Combination products containing butaphosphan and cyanocobalamin are finished pharmaceutical presentations, not bulk APIs; the 99% pharma-grade article described here is the starting material for compounding such combinations, not a substitute for them. Formulators must also distinguish butaphosphan from inorganic phosphate salts and from other phosphonic acid derivatives used in medicine (e.g., etidronate disodium, CAS 7414-83-7): the latter act as bisphosphonate bone-resorption inhibitors, whereas butaphosphan functions as a hepatic metabolic stimulant; selecting the wrong phosphorus compound based solely on the shared phosphonic acid functionality leads to a complete absence of therapeutic intent. Published data for comparative stability between free acid and salt forms under accelerated storage conditions is limited, and formulators are directed to generate side-by-side compatibility studies during preformulation.

Oral liquid presentations containing butaphosphan are prepared at concentrations of 5–20 g/L in purified water with pH adjusted to 6.0–6.5; the buffering system typically comprises citrate or phosphate at 10–25 mM to maintain the free-acid/salt equilibrium within the stability window. Preservative selection requires compatibility screening because the secondary amine moiety can participate in degradation reactions with certain preservative systems under acidic conditions; published data for these specific configurations is limited and screening under ICH Q1A(R2) accelerated conditions is recommended before commercial scale-up. The primary hydrolytic risk in aqueous media is scission of the N–butyl bond at pH below 4.0 or above 8.0, and pH excursion outside this range during manufacture or storage is the dominant driver of out-of-specification assay results in long-term stability programmes. The 99% pharma-grade article therefore serves the five dosage-form routes—tablet, capsule, granule, injection, and oral liquid—through a single specification platform, with the parenteral route differentiated solely by the additional endotoxin acceptance criterion and the requirement for aseptic or terminal sterilisation processing.